

Substitute for form 1449/PTO

(Use as many sheets as necessary)

Complete if Known

Application Number	10/627,499
Filing Date	07/25/2003
First Named Inventor	Kink et al.
Art Unit	1646
Examiner Name	Xie
Attorney Docket Number	OPHD0-8311

Sheet	1	of	1
-------	---	----	---

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner
Signature**

Date	Considered
11/1/78	11/1/78
11/2/78	11/2/78
11/3/78	11/3/78
11/4/78	11/4/78
11/5/78	11/5/78
11/6/78	11/6/78
11/7/78	11/7/78
11/8/78	11/8/78
11/9/78	11/9/78
11/10/78	11/10/78
11/11/78	11/11/78
11/12/78	11/12/78
11/13/78	11/13/78
11/14/78	11/14/78
11/15/78	11/15/78
11/16/78	11/16/78
11/17/78	11/17/78
11/18/78	11/18/78
11/19/78	11/19/78
11/20/78	11/20/78
11/21/78	11/21/78
11/22/78	11/22/78
11/23/78	11/23/78
11/24/78	11/24/78
11/25/78	11/25/78
11/26/78	11/26/78
11/27/78	11/27/78
11/28/78	11/28/78
11/29/78	11/29/78
11/30/78	11/30/78

4/13/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

U.S. Department of
Patent and Trademark Office

Serial No.: 10/627,499

Applicant: John A. Kink *et al.*

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Use Several Sheets If Necessary)

(37 CFR § 1.98(b))

Filing Date: 7/25/2003

Group Art Unit: 1646

U.S. PATENT DOCUMENTS

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

X2	24	Polson <i>et al.</i> , "Antibodies to Proteins from Yolk of Immunized Hens," <i>Immunol. Comm.</i> , 9:495-514 (1980)
↓	25	Okayasu <i>et al.</i> , "A Novel Method in the Induction of Reliable Experimental Acute and Chronic Ulcerative Colitis in Mice," <i>Gastroenterology</i> , 98:694-702 (1990)
	26	Kojouharoff <i>et al.</i> , "Neutralization of tumour necrosis facto (TNF) but not of IL-1 reduces inflammation in chronic dextran sulphate sodium-induced colitis in mice," <i>Clin. Exp. Immunology</i> , 107: 353-358 (1997)
	27	Olson <i>et al.</i> , "Antiserum to Tumor Necrosis Factor and failure to Prevent Murine Colitis," <i>J. Pediatric Gastroenterology and Nutrition</i> 21: 410-418 (1995)
↓	28	Stack <i>et al.</i> , "The Effects of CDP571, An Engineered Human IgG α 4 Anti-TNF α Antibody in Crohn's Disease", <i>Gastroenterology</i> , 110:A1018 (1996)


Examiner:

Date Considered:

EXAMINER:

Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 Commerce (Modified)		U.S. Department of Patent and Trademark Office		Attorney Docket No.: OPHD-08311	Serial No.: 10/627,499
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary) (37 CFR § 1.98(b))				Applicant: John A. Kink <i>et al.</i>	
				Filing Date: 7/25/2003	
Group Art Unit: 1646					
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)					
X2	29	Rutgeerts <i>et al.</i> , "Retreatment with Anti-TNF- α Chimeric Antibody (cA2) Effectively maintains cA3-Induced remission in Crohn's Disease," <i>Gastroenterology</i> 112:A1078 (1997)			
	30	Van Dulleman <i>et al.</i> , "Treatment of Crohn's Disease with Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody (cA2)," <i>Gastroenterology</i> 109:129-138 (1995)			
	31	Targan <i>et al.</i> , "A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease," <i>New England Journal of Medicine</i> , 337:1029-1035 (1997)			
	32	Plevy <i>et al.</i> , "A Role for TNF- α and Mucosal T Helper-1 Cytokines in the Pathogenesis of Crohn's Disease," <i>Journal of Immunology</i> , 6277-6282 (1997)			
	33	Sartor, "Current Concepts of the Etiology and Pathogenesis of Ulcerative Colitis and Crohn's Disease," <i>Inflammatory Bowel Disease</i> , 24:475-507 (1995)			
	34	Sartor, "Pathogenesis and Immune Mechanisms of Chronic Inflammatory Bowel Diseases," <i>Gastroenterology</i> , 92:5S-11S (1997)			
	35	Robinson, "Optimizing Therapy for Inflammatory Bowel Disease," <i>American Journal of Gastroenterology</i> , 92:12-17 (1997)			
	36	Targan and Shanahan, "Pseudomembranous Colitis and Clostridium Difficile Infection," <i>Inflammatory Bowel Disease From Bench to Bench</i> , 51:743-755 (1994)			
	37	Ogorek and Fisher, "Differentiation Between Crohn's Disease and Ulcerative Colitis," in <i>Inflammatory Bowel Disease</i> , Katz, ed., 78:1249-1257 (1994)			
	38	Cameron, "Anti-TNF- α treatments set to mop up in rheumatoid arthritis," <i>Research and Development</i> , pp.9-10 (1998)			
	39	Elliott <i>et al.</i> , "Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis," <i>Lancet</i> , 344:1105-1110 (1994)			
	40	Elliott <i>et al.</i> , "Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis," <i>Lancet</i> 344:1125-1127 (1994)			
	41	Gibson, "Inflammatory Bowel Disease Current Concepts in Pathogenesis and Therapy," <i>Clin. Immunother.</i> , 2(2):135-160 (1994)			
	42	Bell and Wallace, "Inflammatory Bowel Disorders Current and Future Drugs that Modulate Adhesion Molecules," <i>Biodrugs</i> , 7(4):273-284 (1997)			
	43	Opal <i>et al.</i> , "Potential Hazards of Combination Immunotherapy in the Treatment of Experimental Septic Shock," <i>J. Infect. Dis.</i> , 173:1415-1421 (1996)			
	44	Russell <i>et al.</i> , "Combined Inhibition of Interleukin-1 and Tumor Necrosis Factor in Rodent Endotoxemia: Improved Survival and Organ Function," <i>J. Infect. Dis.</i> , 171:1528-1538 (1995)			
	45	Levine <i>et al.</i> , "Intravenous Immunoglobulin Therapy for Active, Extensive and Medically Refractory Idiopathic Ulcerative or Crohn's Colitis" <i>Am J Gastroenterol</i> , 87:91-100 (1992)			
	46	Neurath <i>et al.</i> , "Predominant Pathogenic role of Tumor Necrosis Factor in Experimental Colitis in Mice," <i>Eur J Immunol</i> 27:1743-1750 (1997)			
	47	Neurath <i>et al.</i> , "Antibodies to Interleukin 12 Abrogate Established Experimental Colitis in mice," <i>J Exp Med</i> 182:1281-1290 (1995)			
	48	Feldmann <i>et al.</i> , "Cytokine Expression and Networks in Rheumatoid Arthritis: Rationale for Anti-TNF α Antibody Therapy and its Mechanism of Action," <i>J Inflammation</i> 47:90-96 (1996)			
	49	Reimund <i>et al.</i> , "Increased production of tumor necrosis factor- α , interleukin-1- β and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease" <i>Gut</i> 39:684-689 (1996)			
	50	Duchmann <i>et al.</i> , "Tolerance towards resistant intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12," <i>Eur J Immunol</i> 26:934-938 (1996)			
	51	Tsubokura <i>et al.</i> , "Oral administration of antibodies as prophylaxis and therapy in <i>Campylobacter jejuni</i> -infected chickens," <i>Clin Exp Immunol</i> 108:451-455 (1997)			
	52	Nicholls <i>et al.</i> , "Cytokines in stools of children with inflammatory bowel disease or infective diarrhoea," <i>J Clin Path</i> 46:757-760 (1993)			
	53	Tjellström <i>et al.</i> , "Oral immunoglobulin treatment in Crohn's disease," <i>Acta Paediatr</i> 86:221-223 (1997)			
✓	54	Rubalteli <i>et al.</i> , "Prevention of necrotizing enterocolitis in neonates at risk by oral administration of monomeric IgG," <i>Dev Pharmacol Ther</i> 17:138-143 (1991)			
Examiner:		Date Considered:		4/13/07	
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					

FORM PTO-1449 Commerce (Modified)		U.S. Department of Patent and Trademark Office		Attorney Docket No.: OPHD-08311	Serial No.: 10/627,499
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)				Applicant: John A. Kink <i>et al.</i>	
(37 CFR § 1.98(b))				Filing Date: 7/25/2003	Group Art Unit: 1646
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)					
55	Armastron <i>et al.</i> , "Tumor necrosis factor and inflammatory bowel disease," <i>British Journal of Surgery</i> 84:1051-1058 (1997)				
56	Monteleone <i>et al.</i> , "Interleukin 12 (IL-12) is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells (LPMCs)," <i>Gastroenterology</i> 112:1169-1178 (1997)				
57	Starnes <i>et al.</i> , "Anti-IL-6 monoclonal antibodies protect against lethal <i>Escherichia coli</i> infection and lethal tumor necrosis factor-alpha challenge in mice" <i>J Immuno</i> 12:4185-4191 (1990)				
58	Doherty <i>et al.</i> , "Evidence for IFN-gamma as a mediator of the lethality of endotoxin and tumor necrosis factor-alpha" <i>J Immuno</i> 5:1666-1670 (1992)				
59	Manthey <i>et al.</i> , "The role of cytokines in host responses to endotoxin" <i>Reviews in Med Microbio</i> 3:72-79 (1992)				
60	Dalekos, <i>et al.</i> , "High concentrations of soluble interleukin-2 receptors and interleukin-6 in active ulcerative cells" <i>Hellenic J Gastro</i> 8:319-327 (1995)				
61	Evans, <i>et al.</i> , "Treatment of ulcerative colitis with an engineered human anti-TNF-alpha antibody CDP571" <i>Aliment Pharmacol Ther</i> 11:1031-1035 (1997)				
62	Hoang, <i>et al.</i> , "Symposium: Role of cytokines in inflammatory bowel disease" <i>Acte Gastro-Enterologica Belgica</i> 57:219-223 (1994)				
63	van Hogeand, <i>et al.</i> , "Selective immunomodulation in patients with inflammatory bowel disease-future therapy or reality?" <i>Netherlands J of Med</i> 48:64-67 (1996)				
64	Zacharchuk <i>et al.</i> , "Macrophage-mediated cytotoxicity: Role of a soluble macrophage cytotoxic factor similar to lymphotoxin and tumor necrosis factor," <i>PNAS USA</i> 80:6341-6345 (1983)				
65	Zacharchuk, Charles Michael, "A Macrophage Cytotoxic Factor: Immunochemical and Functional Characterization," Dissertation Abstract (1983)				
66	Pennica <i>et al.</i> , "Human tumor necrosis factor: precursor structure, expression and homology to lymphotoxin," <i>Nature</i> 312:724-729 (1984)				
67	Ruff, Michael Roland, "Mechanism of Action of a Serum Oncolytic Protein, Rabbit Tumor Necrosis Factor," Dissertation Abstract. (1980)				
68	Beck <i>et al.</i> , "Cytokines in inflammatory bowel disease," <i>Mediators of Inflammation</i> 6:95-103 (1997)				
69					
70					
71					
72					
73					
74					
75					
76					
77					
78					
79					
Examiner: 		Date Considered: 4/13/07			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					